Deringer J R, Ely R J, Stauffacher C V, Bohach G A
Department of Microbiology, Molecular Biology and Biochemistry, University of Idaho, Moscow 83843, USA.
Mol Microbiol. 1996 Nov;22(3):523-34. doi: 10.1046/j.1365-2958.1996.1381506.x.
The goal of this study was to investigate the molecular interaction between superantigens and the T-cell receptor (TCR). Using a quantitative polymerase chain reaction (PCR) to assess T-cell proliferation profiles, we found that SEB, SEC1, SEC2 and SEC3 expanded human T cells bearing V beta 3, V beta 12, V beta 13.2, V beta 14, V beta 15, V beta 17 and V beta 20. SEC2 and SEC3 have the additional ability to expand T cells bearing V beta 13.1, and their expansion of V beta 3 was markedly reduced compared to SEB and SEC1. Based on the activity of SEC1 mutants containing single amino acid substitutions, we concluded that the differential abilities of these native toxins to stimulate V beta 3 and V beta 13.1 was determined by the residue in position 26, located in the base of the SEC alpha 3 cavity. The SEC1 mutant, in which Val in position 26 was substituted with the analogous SEC2/SEC3 residue (Tyr), generated a V beta expansion profile that was indistinguishable from those generated by SEC2 and SEC3. Using these findings, the co-ordinates of a recently reported murine TCR beta-chain crystal structure, and other documented information, we propose a compatible molecular model for the interaction of SEC3 with the T-cell receptor. In this model complex, the complementarity-determining regions (CDRs) 1 and 2 and the hypervariable loop 4 of the V beta element contact SEC3 predominantly through residues in the alpha 3 cavity of the toxin. CDR3 of the beta chain is not involved in any toxin contacts. The proposed model not only includes contacts identified in previous mutagenesis studies, but is also consistent with the ability of tyrosine and valine in position 26 to differentially affect the expansion of V beta s 3 and 13.1 by the SEC superantigens.
本研究的目的是调查超抗原与T细胞受体(TCR)之间的分子相互作用。我们使用定量聚合酶链反应(PCR)来评估T细胞增殖谱,发现SEB、SEC1、SEC2和SEC3可使携带Vβ3、Vβ12、Vβ13.2、Vβ14、Vβ15、Vβ17和Vβ20的人T细胞扩增。SEC2和SEC3还具有使携带Vβ13.1的T细胞扩增的能力,与SEB和SEC1相比,它们对Vβ3的扩增明显减少。基于含有单个氨基酸取代的SEC1突变体的活性,我们得出结论,这些天然毒素刺激Vβ3和Vβ13.1的不同能力是由位于SECα3腔底部第26位的残基决定的。第26位的缬氨酸被类似的SEC2/SEC3残基(酪氨酸)取代的SEC1突变体,产生的Vβ扩增谱与SEC2和SEC3产生的扩增谱无法区分。利用这些发现、最近报道的小鼠TCRβ链晶体结构的坐标以及其他已记录的信息,我们提出了一个SEC3与T细胞受体相互作用的兼容分子模型。在这个模型复合物中,Vβ元件互补决定区(CDR)1和2以及高变环4主要通过毒素α3腔中的残基与SEC3接触。β链的CDR3不参与任何毒素接触。所提出的模型不仅包括先前诱变研究中确定的接触,而且还与第26位的酪氨酸和缬氨酸对SEC超抗原差异影响Vβ3和13.1扩增的能力一致。